Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Cervical cancer screening device maker TruScreen Group (ASX/: TRU) has gained fresh clinical backing for its technology, with a newly published peer-reviewed study reporting superior diagnostic performance when its device is paired with high-risk HPV testing.

The independent study, conducted at Panzhihua Central Hospital in China and published in the Journal of Sichuan University, compared TruScreen combined with high-risk human papillomavirus testing (hr-HPV) against the conventional Thinprep cytology test (TCT) paired with HPV testing. The results suggest the TruScreen approach may offer a more accurate alternative to cytology-based screening pathways.

While modest in scale, involving 297 women aged between 21 and 57, the trial provides further clinical validation for the company’s opto-electronic screening technology and its potential role in global cervical cancer detection programs.

Head-to-head comparison with conventional cytology

The trial assessed the effectiveness of two screening combinations in detecting cervical lesions - low-grade squamous intraepithelial lesions (LSIL+) and high-grade lesions (HSIL+), both indicators of potential cervical cancer progression.

Histopathology results from the cohort identified 128 LSIL+ cases and 67 HSIL+ cases, representing 43.1% and 22.6% of the study population respectively.

Against this benchmark, the TruScreen plus hr-HPV combination demonstrated stronger diagnostic metrics than the conventional cytology-based method. Specifically, the study found that:

• TruScreen + hr-HPV delivered a higher area under the ROC curve (AUC), indicating improved overall diagnostic accuracy.

• The combination produced high sensitivity for detecting HSIL+ lesions.

• Specificity and negative predictive value were also superior to the TCT + hr-HPV approach.

In plain English, the technology was more accurate at identifying both true positives and true negatives.

The study authors concluded that the TruScreen co-testing approach “demonstrates superior performance in cervical cancer screening compared with TCT combined with hr-HPV test and may serve as an alternative to conventional cytology-based methods in China.”

A growing clinical evidence base

For investors, the study adds another brick to the clinical wall supporting TruScreen’s technology.

The company says its evidence base now comprises more than 30 clinical trials and large-scale studies covering over 40,000 women globally.

The latest results align with the much larger COGA study involving nearly 15,000 women, published in early 2026 in BMC Cancer. That study also concluded that TruScreen outperformed conventional liquid-based cytology and hr-HPV testing when used as a primary screening tool.

Clinical validation is particularly important for medical device companies seeking broader regulatory adoption and integration into national screening programs. In many jurisdictions, health authorities require extensive real-world evidence before recommending new diagnostic technologies.

Why TruScreen’s technology matters

Unlike traditional Pap smears or cytology-based tests, TruScreen’s device uses opto-electronic sensors to analyse cervical tissue in real time.

The handheld device applies low-level electrical and optical stimuli to the cervix and uses AI-enabled algorithms to detect abnormalities instantly. This means results are available at the point of care without requiring tissue samples to be sent to pathology laboratories.

That distinction is significant for countries with limited healthcare infrastructure, where access to cytology labs or trained pathologists can be scarce.

According to executive chairman Tony Ho, the technology is particularly suited to screening initiatives in emerging markets.

“These results continue to support TruScreen’s suitability for integration into cervical cancer screening initiatives globally, particularly in markets where access to pathology infrastructure is limited,” he said.

Strategic tie-up with HPV testing partner

The study also provides additional validation for TruScreen’s partnership with Dalton BioSciences, a Chinese manufacturer of HPV diagnostic kits.

Dalton’s HPV DNA testing products are designed to identify high-risk strains of the virus associated with cervical cancer and can be combined with TruScreen’s device in a co-testing strategy. The arrangement allows TruScreen to distribute HPV in-vitro diagnostic products through its global network.

From a commercial perspective, combining device-based screening with HPV testing potentially expands the company’s addressable market and creates additional revenue streams through consumables and testing kits.

Global footprint steadily expanding

TruScreen markets its flagship device, the TruScreen Ultra, as a primary cervical cancer screening tool that eliminates the need for tissue sampling and laboratory processing.

The device holds regulatory approvals across multiple jurisdictions including Australia, the United Kingdom, China, Saudi Arabia, Mexico and Russia, with ministry-level approvals in countries such as Vietnam and Israel.

Distribution now spans 29 countries, with a manufacturing facility in China established in 2021 to support the local market.

Operational metrics also point to growing utilisation. In the 2024 financial year alone, more than 200,000 examinations were conducted using TruScreen devices worldwide, based on sales of single-use sensors.

The investor lens

For ASX investors, the announcement underscores a familiar theme in medtech - clinical validation precedes commercial adoption.

While a 297-patient study is not transformative on its own, the steady accumulation of peer-reviewed data strengthens the case for broader use of the technology in national screening programs and hospital networks.

If adoption continues to build across emerging healthcare markets where laboratory infrastructure is limited, TruScreen’s real-time screening model could find a receptive audience.

In the meantime, each additional study helps bolster the company’s central claim: that AI-enabled, point-of-care cervical screening may eventually challenge the decades-old cytology status quo.

Audeara’s push to position itself at the heart of the emerging Auracast audio ecosystem has taken another step forward, with the company securing fresh purchase orders from Taiwanese partner Clinico Inc.

The Brisbane-based hearing technology group has received initial orders worth roughly $164,000 tied to the launch of three new white-label commercial programs under the Clinico brand. The initiatives include two Auracast-enabled devices built around Audeara’s BT-03 Audio Broadcaster platform, alongside Clinico-branded accessories and a dedicated programming interface.

While the dollar value of the opening orders is modest, the strategic significance lies in the expansion of a partnership that already delivered the Clinico Sound Earbuds CS1 launch in Taiwan. The new programs broaden the commercial footprint of Audeara’s technology platform and provide another pathway for scaling its AUA Technology division internationally.

Management frames the development as evidence that the company’s integration model - embedding Auracast broadcasting technology within partner product ecosystems - is beginning to gain traction.

The BT-03 broadcaster enters the stage

Central to the expansion is the recently launched BT-03 Audio Broadcaster, a device designed to deliver shared audio streams using the Bluetooth LE Audio Auracast standard.

Auracast allows a single transmitter to broadcast audio that multiple compatible devices can receive simultaneously, without the need for traditional pairing. In practical terms, that means a venue could stream audio from a television, lecture or announcement directly to dozens or even hundreds of personal listening devices.

Audeara launched the BT-03 into the Australian market at a recommended retail price of $399, marking the company’s first dedicated infrastructure product aimed at the broader Auracast ecosystem.

The device has been engineered to integrate into existing audio-visual systems while supporting deployment across multi-room environments such as lecture halls, hospitals or hospitality venues. Early channel validation has reportedly been achieved via AV installers and consumer audio retailers in Australia, suggesting initial commercial interest beyond the company’s traditional hearing health base.

For investors, the broader significance lies in how Auracast adoption typically requires two elements - broadcast infrastructure and compatible personal listening devices. Audeara is positioning itself to supply both layers.

From hearing tech to ecosystem player

Historically, Audeara has been known for personalised audio solutions designed to assist people with hearing challenges. The Auracast strategy represents a shift toward becoming a platform provider within a new wireless audio standard.

The company’s product suite now spans infrastructure devices such as the BT-03 broadcaster, alongside listening hardware including Audeara Buds and Bluetooth LE Audio transceivers. Together, these products form the foundation of a broader listening ecosystem capable of supporting large-scale shared audio environments.

Clinico’s white-label devices effectively embed Audeara’s broadcasting infrastructure within a partner’s own product range, giving the Australian firm exposure to new markets without needing to build its own distribution network in each region.

Target deployment environments extend well beyond consumer headphones. Potential applications include universities and training facilities, hospitals and aged-care settings, as well as hospitality venues and entertainment spaces where shared audio is required but personal listening is preferred.

Managing director and chief executive Dr James Fielding said the latest orders underline the strength of the relationship with Clinico and the commercial opportunity emerging around Auracast-enabled infrastructure.

“The receipt of purchase orders from Clinico reflects the continued strength of our partnership and the shared opportunity we identified as part of Clinico’s broader strategic investment,” he said.

Fielding added that Auracast transmitters are already deployed in universities globally and that white-label integration represents the next step in scaling adoption into consumer markets.

International expansion in sight

Beyond the Clinico partnership, Audeara is also working to extend the reach of the BT-03 broadcaster into major global markets. Certification processes are underway across the United States, Japan, Taiwan, Canada and the European Union, which could significantly expand the addressable market if approvals are secured.

Industry interest in Auracast appears to be building as well. Fielding noted that discussions with global product leaders at the recent Integrated Systems Europe conference in Barcelona reinforced the view that demand for Auracast-compatible solutions is increasing.

That trend could be crucial. Much like early Bluetooth or Wi-Fi adoption cycles, the value of Auracast hinges on network effects - the more infrastructure deployed, the more valuable compatible devices become, and vice versa.

Audeara’s strategy is to sit squarely in the middle of that ecosystem.

A platform approach to growth

The company’s AUA Technology division is built around three pillars - embedding its broadcast and audio processing capabilities into partner product lines, expanding white-label programs, and leveraging infrastructure deployments to encourage wider Auracast adoption.

If successful, the model could diversify revenue streams beyond the company’s traditional consumer products and position Audeara as a technology partner rather than simply a hardware vendor.

For now, the initial Clinico orders are small in financial terms. But they serve as an early signal that Audeara’s ecosystem approach is starting to translate into commercial partnerships.

In the fast-evolving world of wireless audio standards, the real prize may lie not just in selling devices - but in becoming the plumbing behind them.

Adisyn has added an intriguing new string to its graphene bow, unveiling early-stage test work that suggests its materials expertise could extend beyond semiconductors and into the world of radar signature management.

The market has primarily valued the company for its ambition to commercialise a low-temperature atomic layer deposition process to grow graphene directly onto semiconductor wafers. Now, laboratory work conducted with Tel Aviv University indicates the same core materials capability may also help drones become far less visible to radar systems.

For a small-cap with big aspirations, the optionality is notable - even if the semiconductor program remains centre stage.

20dB and counting - what the test results mean

The headline number is a radar reflection reduction of up to 20dB in controlled lab testing, achieved using graphene-enhanced composite materials. In plain English, that is a substantial attenuation of reflected radar energy compared with baseline materials.

The company is now targeting optimisation work that could push the reduction towards 30dB. That is not just a marginal gain. A 30dB reduction implies the radar cross-section - effectively how large an object appears to radar - could shrink by a factor of 1,000.

To illustrate the point, a drone that might previously have presented as a one square metre object to a radar system could, with that level of suppression, appear closer to 10 square centimetres - roughly insect-sized in radar terms.

Such performance metrics are catnip to defence technologists. Radar signature management is an increasingly critical design factor in UAV, aerospace and defence systems, particularly as unmanned platforms become smaller, lighter and more widely deployed.

The practical implications are straightforward. A smaller radar signature means later detection, shorter interception windows and greater survivability in contested environments. Even incremental gains in this domain can materially change mission profiles.

Academic muscle behind the science

The program is being led by Professor Pavel Ginzburg, a full professor of electrical engineering at Tel Aviv University with a research focus spanning radar physics, electromagnetics and scattering control.

For investors wary of blue-sky materials claims, the involvement of a recognised radar physicist lends scientific credibility to the proof-of-concept phase. That does not de-risk commercialisation, but it does suggest the work is grounded in serious academic expertise rather than marketing exuberance.

Importantly, the radar initiative sits within an existing collaboration framework under which Adisyn holds a 12-month option to secure exclusive, perpetual rights to the technology, subject to agreed terms.

That option structure gives the company time to further validate scalability, consistency and commercial viability before making a binding commitment.

Semiconductor ambitions remain the main game

Investors should not misread the pivot. Management has been explicit that the company’s primary focus remains the development and commercialisation of its low-temperature ALD graphene deposition technology for semiconductor interconnect applications.

That core program aims to address the looming performance constraints of copper interconnects in advanced chips. If successful, direct graphene growth at low temperatures could enable faster, stronger and more energy-efficient processing.

Progress on that front is said to be on schedule, with further updates flagged in coming weeks.

The radar work is positioned as a parallel, secondary stream - effectively an opportunistic extension of the company’s graphene capability into adjacent high-value markets.

Optionality versus execution risk

From a market perspective, the stealth composite angle introduces a fresh narrative lever. Defence and aerospace applications tend to attract premium valuations, particularly where enabling materials technology is concerned.

However, this remains early-stage technical validation. Laboratory results under controlled conditions are a long way from field-deployable, certifiable materials integrated into complex platforms. Questions of manufacturing scalability, durability, regulatory clearance and end-user adoption all lie ahead.

Moreover, the semiconductor opportunity alone is already ambitious. Pursuing dual pathways - semiconductors and advanced defence composites - will test management bandwidth and capital allocation discipline.

Still, for a company built around graphene know-how, demonstrating that the same materials science can address multiple multibillion-dollar markets is strategically astute.

In small-cap land, optionality is valuable - provided it does not morph into distraction. Adisyn’s challenge will be to advance its semiconductor interconnect roadmap while methodically progressing radar signature optimisation, letting the data rather than the hype do the heavy lifting.

For now, investors have been handed an additional proof point that the company’s graphene platform may have broader relevance than initially assumed. Whether that translates into commercial traction will depend on what the next round of test results reveals.

Archer Materials (ASX: AXE) has delivered a half year update that reads less like blue-sky research and more like a company methodically ticking off milestones on two technically demanding fronts - quantum computing and medical diagnostics.

For the six months to 31 December 2025, Archer trimmed its net loss to $2.99 million from $4.42 million previously, while pressing ahead with its 12CQ quantum project and advancing its potassium-sensing Biochip toward prototype and clinical readiness .

The numbers remain those of a development-stage technology house. But the operational progress suggests a company intent on proving it can build devices, not just publish papers.

Quantum readout - from theory to current flow

The headline technical achievement was electrical readout of quantum states in Archer’s proprietary carbon-based qubit materials. In plain English, the company demonstrated on-chip electrical detection of electron spin resonance using its EDMR devices, validating a path away from complex optical systems toward semiconductor-compatible architectures .

Executive chair Greg English described the breakthrough as validating “a scalable and semiconductor-compatible pathway toward practical quantum devices” . The emphasis on CMOS compatibility is deliberate. If quantum hardware is to sit alongside conventional electronics, it must eventually fit within the industrial logic of wafer-scale manufacturing.

Archer reported reproducible device performance across multiple fabrication cycles and demonstrated gating in its single-electron transistor architecture. Electron spin lifetimes exceeding 0.4 microseconds at room temperature were achieved in carbon films synthesised on 1-inch silicon wafers, reinforcing claims of material uniformity and scalability .

The roadmap now points to a targeted qubit demonstration in 2026, with early spin-state readout testing underway . That will be the litmus test for whether this remains a promising platform or graduates into a credible qubit contender.

TMR sensors - cold comfort for quantum systems

As part of the 12CQ program, Archer also demonstrated magnetic field measurements at cryogenic temperatures using its tunnelling magnetoresistance sensors .

While less glamorous than qubits, TMR sensors are critical to stabilising and monitoring quantum systems operating in extreme environments. The company sees applications not only in quantum hardware but also in aerospace and defence contexts. The cryogenic performance milestone nudges the technology further along the development curve, though commercial timelines remain undefined.

Biochip - dual track to the clinic

If quantum is the long game, the Biochip is pitched as the nearer-term commercial play.

Archer reported potassium measurement precision within plus or minus 0.3 mM in human blood, aligned with clinical laboratory standards . The company is pursuing a dual-platform strategy, developing both graphene-based and silicon-based devices to de-risk manufacturing and supply chains.

The silicon pathway received a boost through collaboration with IMEC, with first-stage results demonstrating accuracy equivalent to graphene devices and faster readout times . Silicon’s attraction lies in scalability and access to established semiconductor fabrication infrastructure.

Management says chip design is complete, fabrication is scheduled to commence and readout electronics are nearing final assembly, positioning the program for prototype-level testing this year . An alpha prototype integrating the Biochip, test cartridge and electronics was announced post period end on 30 January 2026, demonstrating stable system-level operation with clinical-grade accuracy .

Clinical trials are targeted for 2026, with regulatory pathway planning underway . The company ultimately sees the potassium test as a beachhead for broader diagnostic applications.

The ledger - steady burn, solid buffer

Financially, Archer remains pre-revenue, with no ordinary revenue recorded for the half . Direct expenditure on quantum and Biochip research totalled $3.04 million, up from $2.52 million a year earlier . Share-based payments fell sharply to $237,020 from $1.67 million, helping narrow the overall loss .

Cash and cash equivalents stood at $3.69 million at period end, with a further $6.58 million in short-term term deposits . The group has no corporate debt . Net tangible assets per share slipped to 5.22 cents from 7.20 cents at 30 June 2025, reflecting the steady drawdown typical of R&D-intensive businesses .

The R&D tax incentive remains a material contributor, with $1.38 million recognised as other income for the period .

Patents, partnerships and personnel

Archer continues to build out its intellectual property portfolio across quantum and Biochip technologies, with multiple patents granted and pending in key jurisdictions including the US, Europe and Asia .

The company expanded collaborations with Emergence Quantum and CSIRO, the latter focused on quantum machine learning applications in fraud detection . These alliances signal an intent to explore revenue-adjacent opportunities beyond core hardware.

On the board front, Andrew Just joined as non-executive director in December, bringing medical device and health industry experience that aligns neatly with the Biochip push .

From lab to leverage

Archer’s challenge remains consistent - converting credible technical progress into commercial leverage before the cash balance becomes the dominant narrative.

The half year result shows tangible movement on qubit readout, material scalability and diagnostic accuracy. The next 12 months, with a targeted qubit demonstration and Biochip prototype testing, will determine whether Archer can shift from being an intriguing research story to a company with defined commercial pathways.

For patient investors, the science is getting sharper. The market will want to see whether the revenue horizon comes into focus.

Environmental technology minnow Calix Limited has chalked up a sturdy first half for FY26, pairing double digit revenue growth with sharply improved cash discipline and a clutch of heavyweight commercial alliances.

For a company long associated with promise and platform potential, the latest numbers suggest a more grounded story is emerging - one built on magnesia cash flows and capital light ambitions in lithium and green iron.

Magnesia does the heavy lifting

For the six months to 31 December 2025, product and services revenue rose 21 per cent to $16.3 million, up from $13.5 million in the prior corresponding period . The engine room was magnesia, with revenue jumping 48 per cent to $15.8 million.

Gross margins expanded to 40 per cent from 37 per cent, driving gross profit up 37 per cent to $6.7 million . In a market that has been unforgiving toward early stage industrial tech plays, margin expansion is not just a footnote - it is validation.

Management has been at pains to emphasise focused business delivery, and the cost line bears that out. Operating costs were cut 30 per cent to $15.6 million, while net operating cash outflows shrank 65 per cent to $6.2 million . That is not yet cash flow positive territory, but it is a material narrowing of the gap.

Grant funding and tax incentives contributed $1.3 million for the half , a modest decline year on year but still an important non dilutive funding stream.

Lithium pivot - capital light or capital fright?

The more intriguing development sits in lithium.

Calix consolidated $6.5 million of capital expenditure relating to its share of the unincorporated joint venture for the Mid Stream lithium project during the half, although it made no further cash contribution in the period . Total capex for the half was $7.1 million.

Post balance date, the company signed a binding term sheet with Pilbara Minerals to restructure the Mid Stream project. The proposed deal is expected to remove ongoing funding requirements and execution exposure, release $11.4 million of net capital previously invested and realign lithium commercialisation with Calix’s long term licensing model .

In plain English, Calix appears keen to exit the capital intensive phase and return to what it does best - licensing its electric calcination technology rather than building and funding plants.

Construction of the Mid Stream demonstration plant was completed on budget during the half, marking the company’s first commercial scale electric plant . Technologically significant, yes. Financially, the restructure will determine whether it becomes a balance sheet burden or a springboard.

Blue chip validation gathers pace

If lithium is being de risked, iron and alumina are being quietly advanced with big name partners.

Calix signed a non exclusive Joint Development Agreement with Rio Tinto to support the Zesty Green Iron Demonstration Plant, a deal flagged as contributing more than $35 million of value subject to milestones. A first cash payment of $3 million was received in December following due diligence .

The Zesty project also secured up to $44.9 million in grant funding from the Australian Renewable Energy Agency, subject to matched funding and milestones . Government backing at that scale materially lowers project risk, albeit with the usual strings attached.

Meanwhile, a collaboration with Norsk Hydro will jointly develop Calix’s technology for electrified alumina production. A material testing program and pre FEED study are expected to generate more than $1 million in revenue .

For a company whose pitch rests on decarbonising hard to abate industries, lining up Rio and Hydro is more than a marketing coup. It is industrial validation.

Leilac - progress, but patience required

Calix’s Leilac carbon capture arm completed a pre FEED study for Project ZETA and, after period end, secured a contract to develop carbon dioxide removal materials with Frontier buyers including Google, Stripe and Shopify .

However, financing and permitting for the Leilac 2 project remain in progress, with timing to commence construction still unclear . As ever with first of a kind decarbonisation assets, capital structure and policy settings are as critical as engineering.

Cash flow neutral in sight?

Management expects Calix to be cash flow neutral in calendar 2026, supported by contracted grants, anticipated UK R&D tax incentives, milestone payments from Rio Tinto and continued revenue growth . That guidance excludes the anticipated $11.4 million cash inflow from the Pilbara restructure, which would further bolster liquidity.

Chief executive Phil Hodgson said the company had delivered strongly against its priorities of revenue growth, focused execution and commercial milestones in the first half .

For investors, the narrative is shifting. Calix is no longer just a story about platform potential and planetary slogans. It is beginning to look like a hybrid - part industrial technology licensor, part specialty materials supplier, with blue chip partners underwriting the next stage.

The key questions now are execution and capital discipline. If the lithium restructure proceeds as flagged and Zesty financing locks in, Calix may finally have the financial architecture to match its technological ambition.